Olema Oncology Posts $73.6M Q3 Loss, Cash Falls to $413.8M

Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) reported a third-quarter 2026 net loss of $73.6 million, or $0.73 per basic and diluted share, the company said on 10 November 2026, against a $42.2 million loss in the same quarter a year earlier. Cash, cash equivalents and marketable securities ended the period at $413.8 million, down from $505.4 million at 31 December 2025. Total operating expenses reached $77.5 million for the quarter, versus $45.9 million in the prior-year period.

Context — why Olema's Q3 burn rate matters now

Olema Oncology is a clinical-stage biopharmaceutical company developing targeted therapies for breast cancer. It carries no approved product and therefore no revenue line, which means every dollar of operating expense is funded from the balance sheet the company disclosed.

The comparable the company itself provides is the third quarter of 2025. That quarter produced a $42.2 million net loss on $45.9 million of total operating expenses. The most recent quarter produced a $73.6 million loss on $77.5 million of expenses — a 69% increase in operating spend year over year.

The company attributed the wider loss to several overlapping drivers: increased patient enrollment in the pivotal Phase 3 OPERA-01 trial, strong enrollment in the pivotal Phase 3 OPERA-02 trial, continued advancement of the Phase 1b/2 OP-3136 program, research activities, higher manufacturing and clinical supply costs, and early preparations for a potential commercial launch of palazestrant.

The timing matters because Olema has told investors that top-line data from OPERA-01 is expected in the first quarter of 2027. A company spending at this pace while awaiting a binary readout is effectively converting cash into clinical evidence, and the market will price that evidence when it arrives.

The cash position fell $91.7 million over the nine months from 31 December 2025 to 30 September 2026. Total stockholders' equity declined to $368.8 million from $478.6 million over the same span, while total liabilities rose to $72.2 million from $54.9 million.

Data — what the numbers show

Research and development expenses were the dominant line item. GAAP R&D reached $67.6 million in the quarter, up from $40.0 million a year earlier. Excluding $7.7 million of non-cash stock-based compensation, non-GAAP R&D was $59.9 million, against $37.4 million on the same basis in the third quarter of 2025.

General and administrative expenses were smaller but grew faster in percentage terms. GAAP G&A was $9.9 million versus $5.9 million a year earlier. Non-GAAP G&A, which strips out $4.4 million of stock-based compensation, was $5.5 million versus $4.3 million.

Metric	Q3 2026	Q3 2025
Net loss	$73.6M	$42.2M
GAAP R&D	$67.6M	$40.0M
Non-GAAP R&D	$59.9M	$37.4M
GAAP G&A	$9.9M	$5.9M
Non-GAAP G&A	$5.5M	$4.3M

Interest income partially offset the operating loss. Olema recorded $4.1 million of interest income in the quarter and $13.3 million over the first nine months of 2026, down slightly from $12.2 million in the comparable nine-month period of 2025 despite the larger cash pile at the start of the year.

The nine-month figures show the full trajectory. Net loss for the nine months ended 30 September 2026 was $189.9 million, or $1.89 per share, versus $116.4 million, or $1.36 per share, a year earlier. Total operating expenses for the nine-month period were $202.7 million versus $128.6 million.

The company noted that R&D expenses for the nine months ended 30 September 2025 included a $10.0 million milestone payment tied to the Aurigene Agreement. That one-time item flatters the prior-year comparison on the nine-month line, though the quarterly comparison is unaffected.

Weighted average shares used to compute net loss per share rose to 101.1 million in the quarter from 85.7 million a year earlier, reflecting share issuance. The company said the weighted average includes the effect of pre-funded warrants.

Analysis — what it means for biotech investors

Olema sits in a specific corner of the healthcare sector: clinical-stage oncology names with a single lead asset approaching a pivotal readout. Those companies trade less on quarterly earnings than on the probability the market assigns to their trial data.

The share count increase is a structural signal. Dilution of roughly 15 million weighted average shares year over year means per-share losses fall more slowly than absolute losses rise, and the $0.73 quarterly loss per share reflects that arithmetic.

The counter-argument is straightforward and the company makes it explicitly. Olema described palazestrant as a complete estrogen receptor antagonist and selective estrogen receptor degrader with what it called optimal pharmacokinetic properties, a dual mechanism, and potential for use both as monotherapy and in combination. It also holds FDA Fast Track designation for ER+/HER2- metastatic breast cancer that has progressed after at least one line of endocrine therapy given with a CDK4/6 inhibitor.

The risk is that a clinical-stage company burning roughly $77.5 million per quarter against $413.8 million of cash has a finite runway, and the report does not state a cash runway figure. The company did not disclose how many quarters of funding the current balance represents.

Positioning follows the readout, not the quarter. Investors holding OLMA into the OPERA-01 data release are underwriting a binary clinical event; those who exited on the cash decline are trading the financing risk instead.

Outlook — what to watch next

The company's own calendar lists several near-term items. Preclinical data on selective degradation of KAT6A in estrogen receptor-positive breast cancer is slated for the EORTC-NCI-AACR Symposium in November 2026.

At the 2026 San Antonio Breast Cancer Symposium in December, Olema expects to present data from the Phase 1b/2 study of OP-3136 with fulvestrant, the Phase 1b/2 study of palazestrant with everolimus, and the Phase 1b study of palazestrant with atirmociclib.

The company also said it will initiate enrollment in the fourth quarter of 2026 in a Phase 1b/2 study of OP-3136 combined with darolutamide in mCRPC, in collaboration with Bayer.

The headline catalyst remains top-line data from OPERA-01, guided to the first quarter of 2027. The company separately said enrollment is accelerating in OPERA-02, the first-line trial testing palazestrant with ribociclib.

Olema also appointed Jason O'Byrne as Chief Financial Officer during the quarter. The company said his experience in corporate strategy, capital markets and financial operations would support preparations for catalysts in 2027.

Frequently Asked Questions

What does Olema's Q3 2026 loss mean for retail investors?

It means the company is spending more to run larger trials while earning no product revenue. The quarterly loss of $73.6 million is funded from a $413.8 million cash and securities balance. For a shareholder, the relevant question is not the loss itself but whether the OPERA-01 data expected in the first quarter of 2027 justifies the spending. The report does not state how long the current cash balance lasts.

Why did Olema's research and development costs rise so much?

Olema attributed the increase to several specific items: heavier enrollment in the Phase 3 OPERA-01 and OPERA-02 trials, more manufacturing and clinical supply activity, advancement of the Phase 1b/2 OP-3136 program, and higher personnel costs. Stock-based compensation inside R&D rose $5.1 million year over year, which the company tied to higher grant prices in 2026 and more headcount.

What happens next for Olema Oncology?

The stated near-term events are conference presentations in November and December 2026, initiation of a Phase 1b/2 OP-3136 plus darolutamide study in the fourth quarter of 2026, and top-line OPERA-01 data in the first quarter of 2027. Enrollment in OPERA-02 continues. The company has not disclosed a date for any regulatory submission.

Bottom Line

Olema burned $91.7 million of cash in nine months, and its entire thesis now rests on OPERA-01 data due in early 2027.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.